Cerevel Therapeutics Holdings Faces Securities Fraud Lawsuit, Investors Urged to Contact the Schall Law Firm

Cerevel Therapeutics Holdings is facing a securities fraud lawsuit for allegedly misleading investors about its secondary stock offering and merger with AbbVie. Investors who purchased shares between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, are encouraged to contact the Schall Law Firm before June 3, 2025. The firm is representing investors in a class action lawsuit.

Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is facing a securities fraud lawsuit, alleging that the company misled investors regarding its secondary stock offering and merger with AbbVie, Inc. The lawsuit, filed by Robbins LLP and the Schall Law Firm, claims that Cerevel's public statements were false and materially misleading.

The class action lawsuit, which was filed on behalf of former CERE shareholders, alleges that Cerevel omitted material facts about AbbVie's interest in acquiring the company at a price significantly higher than the secondary stock offering price. According to the complaint, Cerevel's controlling shareholder, Bain Capital Investors, LLC, acquired shares at an artificially depressed price while allegedly possessing material nonpublic information about the acquisition.

On December 6, 2023, Cerevel publicly announced that AbbVie had agreed to acquire the company for $45 per share, a price almost double the secondary offering price of $22.81 per share. The merger allowed Bain to receive a windfall of more than $120 million on the shares it acquired at the artificially depressed offering price.

The lawsuit also seeks damages for investors who held shares as of the January 8, 2024 record date and were damaged by Cerevel's allegedly false and misleading statements in its January 18, 2024 proxy statement. The proxy statement is alleged to have misled investors regarding the true nature and timing of AbbVie's interest in Cerevel.

Investors who purchased shares between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, are encouraged to contact the Schall Law Firm before June 3, 2025, to discuss their rights. The class action lawsuit is ongoing, and until certification occurs, investors are not represented by an attorney. Investors can remain absent class members if they choose to take no action.

The Schall Law Firm and Robbins LLP are recognized leaders in shareholder rights litigation, specializing in securities class action lawsuits and shareholder rights. Both firms have extensive experience representing investors and holding company executives accountable for their wrongdoing. The firms are representing investors on a contingency fee basis, meaning investors pay no fees or expenses.

As of the current date, the lawsuit is in its early stages, and the outcome remains uncertain. Investors are advised to stay informed about the developments and consult with legal professionals if they believe they may be eligible to participate in the class action lawsuit.